Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)

v3.21.2
Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
Series D Convertible Preferred Stock [Member]
Common Stock [Member]
No Par Value [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 29, 2019 $ 3,806 $ 36,848,063 $ (38,578,232) $ (1,726,363)
Balance, shares at Dec. 29, 2019   14,688,726      
Common shares issued for the acquisition of Supera Pharmaceuticals, Inc. a company under common control   (605,089) (605,089)
Common shares issued for the acquisition of Supera Pharmaceuticals, Inc a company under common control, shares     13,096,640      
Effect of the adoption of Topic 842 effective as of January 1, 2019 (1,379) (1,379)
Ending balance, value at Dec. 31, 2019 $ 3,806 36,848,063 (39,184,700.00) (2,332,831.00)
Balance, shares at Dec. 31, 2019   27,785,366      
Private placement of common shares     650,000 650,000
Private placement of common shares, shares     250,835      
Net loss   (981,949) (981,949)
Ending balance, value at Mar. 31, 2020 $ 3,806 37,498,063 (40,166,649) (2,664,780)
Balance, shares at Mar. 31, 2020   28,036,201      
Beginning balance, value at Dec. 31, 2019 $ 3,806 36,848,063 (39,184,700.00) (2,332,831.00)
Balance, shares at Dec. 31, 2019   27,785,366      
Net loss           (2,076,858)
Ending balance, value at Jun. 30, 2020 $ 3,806 38,206,313 (41,261,558) (3,051,439)
Balance, shares at Jun. 30, 2020   28,038,131      
Beginning balance, value at Mar. 31, 2020 $ 3,806 37,498,063 (40,166,649) (2,664,780)
Balance, shares at Mar. 31, 2020   28,036,201      
Stock based compensation for services     14,800 14,800
Stock based compensation for services, shares     1,930      
Stock options issued for debt issuance     693,450 693,450
Net loss   (1,094,909) (1,094,909)
Ending balance, value at Jun. 30, 2020 $ 3,806 38,206,313 (41,261,558) (3,051,439)
Balance, shares at Jun. 30, 2020   28,038,131      
Beginning balance, value at Dec. 31, 2020 $ 4,004 43,411,487 (48,672,525) (5,257,034)
Balance, shares at Dec. 31, 2020   28,553,307      
Net loss (3,089,704) (3,089,704)
Ending balance, value at Mar. 31, 2021 $ 4,004 43,411,487 (51,762,229) (8,346,738)
Balance, shares at Mar. 31, 2021   28,553,307      
Beginning balance, value at Dec. 31, 2020 $ 4,004 43,411,487 (48,672,525) $ (5,257,034)
Balance, shares at Dec. 31, 2020   28,553,307      
Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares           8,335,627
Net loss           $ (21,182,040)
Ending balance, value at Jun. 30, 2021 $ 144,524 100,784,376 (69,854,565) 31,074,335
Balance, shares at Jun. 30, 2021 72,992   37,355,650      
Beginning balance, value at Mar. 31, 2021 $ 4,004 43,411,487 (51,762,229) (8,346,738)
Balance, shares at Mar. 31, 2021   28,553,307      
Reverse merger with Akers Biosciences Inc effective April 16, 2021 $ 144,524 85,748,325 $ (4,004) (43,411,487) 42,477,358
Reverse merger with Akers Biosciences Inc effective April 16, 2021, shares 72,992   8,335,627      
Modification of the terms of 4,188,315 pre-merger MyMD stock options per the terms of the merger agreement 15,036,051 15,036,051
Exercise of prepaid equity forward contracts for common stock
Exercise of prepaid equity forward contracts for common stock, shares           466,716
Net loss   (18,092,336) $ (18,092,336)
Ending balance, value at Jun. 30, 2021 $ 144,524 $ 100,784,376 $ (69,854,565) $ 31,074,335
Balance, shares at Jun. 30, 2021 72,992   37,355,650